This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

William A. Knaus, MD; Frank E. Harrell, PhD; Douglas P. Wagner, PhD
George Washington University Medical Center Washington, DC

JAMA. 1994;272(24):1901.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We write to correct a misunderstanding that appeared in the Editorial by Drs Abraham and Raffin¹ discussing results form the recent Phase III rhIL-1ra Sepsis Syndrome Study Group.² The Editorial states that the APACHE [Acute Physiology and Chronic Health Evaluation] III prediction system used prospectively in this trial² to risk-stratify patients could not be used to identify those who might benefit because it "does not directly reflect the biochemical alterations present in a patient with sepsis." The original JAMA article³ describing the risk prediction method used in this interleukin-1 receptor antagonist trial indicates that the predicted risk of mortality model was specifically designed for use in sepsis trials to account for the physiological profile found in patients who met the sepsis syndrome entry criteria. This was accomplished by using an independent database and determining the predictive importance of a wide range of physiological, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?